RECRUITING

Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).

Official Title

Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA): Implementation of PsOWellTM in PsA

Quick Facts

Study Start:2023-03-10

Study Completion:2025-02

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05631223

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 89 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Population: Patients with Psoriatic Arthritis * Age 18-89. * Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10). * Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit). * Meet CASPAR criteria. * Provision of signed and dated informed consent form. * Willingness to comply with all study procedures and availability for duration of the study. * Has access to a mobile phone or other mobile device.	* Inability to provide informed consent. * Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks. * PsAID score ≤4

Inclusion Criteria

Exclusion Criteria

* Population: Patients with Psoriatic Arthritis
* Age 18-89.
* Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10).
* Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit).
* Meet CASPAR criteria.
* Provision of signed and dated informed consent form.
* Willingness to comply with all study procedures and availability for duration of the study.
* Has access to a mobile phone or other mobile device.

* Inability to provide informed consent.
* Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks.
* PsAID score ≤4

Contacts and Locations

Study Contact

Sarah Hopkins Gillespie

CONTACT

(215) 614-1840

Sarah.Hopkins@Pennmedicine.upenn.edu

Study Coordinator

CONTACT

SpAProgram@pennmedicine.upenn.edu

Principal Investigator

Alexis Ogdie-Beatty, MD

PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Study Locations (Sites)

University Of Pennsylvania

Philadelphia, Pennsylvania, 19104

United States

University of Utah

Salt Lake City, Utah, 84112

United States

Collaborators and Investigators

Sponsor: University of Pennsylvania

Alexis Ogdie-Beatty, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-10

Study Completion Date2025-02

Study Record Updates

Study Start Date2023-03-10

Study Completion Date2025-02

Terms related to this study

Additional Relevant MeSH Terms

Psoriatic Arthritis